Byterna Therapeutics Named a Winner in 2025 'InnoShanghai' Competition, Pioneering In Vivo CAR-T Therapy with AI-Driven Circular mRNA Technology

(Source:Sunshine Nova）

Source: Sunshine Novo

Recently, hosted by the Shanghai Technology Entrepreneurship Center2025 "Innovate in Shanghai" International Innovation and Entrepreneurship CompetitionThe semi-finals have successfully concluded. After multiple rounds of professional evaluations and strict screenings from the preliminary, quarter-final to semi-final stages, Byterna Therapeutics, a partner of Sunshine CRO, has stood out among more than 1,200 participating companies with its AI-driven breakthrough in circular mRNA-based CAR-T technology."Outstanding Enterprise" Award for Startups, becoming a typical representative of hardcore technological innovation in the biopharmaceutical track.

Authoritative Competition, Full of Value

As a benchmark technology innovation competition held continuously for thirteen years in Shanghai, "Create・In Shanghai" has been upgraded to an innovation ecosystem platform featuring "year-round events and city-wide coverage": for the first time, enterprises outside Shanghai are allowed to participate, international cooperation is continually deepened, high-quality incubators and leading enterprises across the city are linked, and industry-specific competitions are set up focusing on key areas such as artificial intelligence, integrated circuits, and biomedicine. The competition takes "early-stage, small-scale, and hard-tech" as its selection orientation, emphasizing technological barriers, industrial value, and transformation potential, forming a systematic technology innovation empowerment mechanism covering from early to growth stages, representing an important weathervane for technology innovation companies within Shanghai and throughout China.

The competition is fierce, and it's not easy to win.

This competition features a large number of high-quality projects with wide distribution. The evaluation process involves experts from multiple fields, investment institutions, and industry players, who jointly assess the entries based on dimensions such as technical principles, degree of innovation, clinical and industrial application prospects, business models, and team capabilities. Byterna Therapeutics stood out in the competition."Hardcore Technology + Clinical Value"Successfully breaking through under comprehensive consideration fully demonstrates the dual recognition of its technical value and market prospects.

Industry Recognition, Ecosystem Empowerment

The award-winning "Innovate in China" enterprise not only serves as an authoritative endorsement of Byterna Therapeutics' technical strength and innovation potential but will also further connect with the comprehensive sci-tech innovation ecosystem resources in Shanghai.Policy and Platform Support, Capital and Industry Synergy, Clinical and Translation PathwaysByterna Therapeutics will take this as a new starting point, deepen cooperation with clinical institutions and industrial chain partners, accelerate the validation of core pipelines and clinical transformation, and drive business growth with high-quality R&D milestones and quantifiable clinical value.

Looking to the future, Byterna Therapeutics will continue to deepen its expertise.AI Empowers New Drug Development, ImprovementCircular mRNA PlatformThe layout of technology, quality, and accessibility, exploreCombination Strategy of In Vivo Delivery and Immune Modulation, committed to creating innovative therapies that meet real clinical needs according to global standards.

Byterna Therapeutics is an innovative biopharmaceutical company driven by AI and circular mRNA technology, focusing on the development of novel drugs for circular mRNA immunotherapy. Leveraging a leading AI algorithm platform, foundational circular mRNA technology, and an in vivo CAR-T new drug platform, we are committed to delivering "safe, effective, accessible, and affordable (SEAA)" in vivo CAR-T cell therapy through nucleic acid drugs, unlocking the full therapeutic potential of CAR-T therapy in autoimmune diseases and cancer, benefiting patients worldwide.